NCT06547476View on ClinicalTrials.gov

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Tucidinostat (chidamide), PD-1 inhibitor (tislelizumab), anlotinib

Tucidinostat (chidamide)，30mg, po., biw PD-1 inhibitor (tislelizumab), 200mg, ivgtt. d1, q3w anlotinib, 12mg, po., d1-14, q3w

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT06547476 - Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed | Biotech Hunter | Biotech Hunter